News

Intimacy health supplier Good Clean Love recognized for entrepreneurship

BY Michael Johnsen

PORTLAND, Ore. — Good Clean Love earlier this week was recognized with the Oregon Entrepreneurs Network’s annual Tom Holce Entrepreneurship award in the development category. Good Clean Love’s founder and CEO Wendy Strgar received the award at a ceremony at downtown Portland’s Hilton Hotel.

Good Clean Love was one of more than 700 businesses throughout Oregon and southwestern Washington to participate based upon the companies’ various achievements and backgrounds. In the preliminary round, Strgar gave a 15-minute presentation, during which committee members asked questions clarifying points about the company’s mission and direction.

With the award, Good Clean Love will receive exclusive coverage on the OEN website and the Portland Business Journal.

The Tom Holce Entrepreneurship Awards originated in 1993. Named after entrepreneur Tom Holce, the awards ceremony recognizes companies that provide jobs, help the economy and have faced many obstacles to growth and success.

Good Clean Love, a certified women-owned business, is a sexual health company with an array of all-natural and organic intimacy products. Good Clean Love products are distributed through Entrenue and can be found in drug stores such as Pharmaca and online at Walgreens.com.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Novo Nordisk seeks to market insulin products

BY Alaric DeArment

PRINCETON, N.J. — Novo Nordisk is seeking approval for two new insulin products, the company said Thursday.

Novo Nordisk announced that it had filed with the Food and Drug Administration for approval of insulin degludec and a co-formulation of insulin degludec and insulin aspart. The products are insulin analogs developed for the treatment of Type 1 and Type 2 diabetes.

"We are very excited about being able to file for the approval of insulin decludec and insulin deluded [with] insulin aspart now also in the U.S.," Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. "This is another significant milestone for Novo Nordisk and for the millions of people with diabetes who require insulin."


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Webinar: FDA’s NDI guidance overreaches

BY Michael Johnsen

WASHINGTON — The New Dietary Ingredient draft guidance, which recently was issued by the Food and Drug Administration, is causing a stir within the dietary supplement industry as experts continue to evaluate what kind of impact the guidance will have on their businesses.

An attorney panelist at a recent industry-sponsored webinar suggested the draft guidance may not stand up in a court of law if finalized and enforced as is.

CRN’s Duffy MacKay, VP scientific and regulatory affairs, moderated the webinar, which included four speakers: FDA’s Daniel Fabricant, director of the Division of Dietary Supplement Programs, Center for Food Safety and Applied Nutrition; FDA’s Dan Levy, supervisor for the New Dietary Ingredient Review Team, Division of Dietary Supplement Programs, CFSAN; James E. Hoadley, senior consultant at EAS Consulting Group; and Ashish Talati, partner at Amin Talati.

The two FDA officials provided an overview of the draft guidance, discussed FDA’s reasoning and rationale for the draft guidance, and explained the process the agency goes through during New Dietary Ingredient Notification reviews. Hoadley offered his best practices for submitting NDI notifications, and Talati shared his legal perspective of the draft guidance, including his opinion that the draft guidance may not withstand judicial review; specifically referencing an established legal test for review of agency actions that he believes undercuts FDA’s position.

"Our industry requested an NDI draft guidance from FDA to help clarify the law and level the playing field; however, this draft guidance overreaches and attempts to perform an end run around the original intent of the Dietary Supplement Health and Education Act," MacKay said. "We hope that FDA is serious about listening to industry concerns about the document and will moderate its interpretation to incorporate many of our concerns about the legal requirements for NDIs.”

The Sept. 14 webinar was co-hosted by the Council for Responsible Nutrition and VIRGO, and is available through Dec. 21 for purchase on-demand, CRN stated.

In addition to the webinar, VIRGO will hold a town hall discussion on the topic at its annual trade show Supply Side West, which will be held October 10-14 in Las Vegas. CRN will hold a wrap-up session at The Conference, “NDIs—What’s Our Next Move?” to explore next steps.  The Conference will be held in Rancho Palos Verdes, Calif., October 19-22 at the Terranea Resort. 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?